Skip to main content

ORKA Oruka Therapeutics, Inc.

Healthcare

96.87 Close 10/30
Since 2024-12-02 +362.2%
Open
94.87
High
97.60
Low
94.75
Prev close
96.65
Volume
633.8K
Amplitude
2.95%
P/B
5.8
52W 25.23 115.52

Is Oruka Therapeutics, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Momentum: Strong, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E -39.22 N/A
Price / book 5.75 85th percentile Expensive
Free-cash-flow yield (%) -1.58 39th percentile Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral ROE, TTM is Average.
ROE, TTM (%) -11.92 30th percentile Average
Operating margin, TTM (%) — N/A
FCF margin, TTM (%) — N/A
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral Diluted EPS growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) — N/A
Diluted EPS growth, TTM YoY (%) -45.47 37th percentile Average
Momentum Strong 240-day return is Top; 60-day return is Good.
60-day return (%) -1.57 63th percentile Good
240-day return (%) 257.72 99th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 75,288,076 85th percentile Top
60-day annualized volatility (%) 53.62 59th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Oruka Therapeutics, Inc. (ORKA) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Oruka Therapeutics, Inc. to every stock like it

AI finds several complementary traits of Oruka Therapeutics, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. (ORKA) peers and tracking

Watchlist

This page refreshes daily after the close. Add Oruka Therapeutics, Inc. to your watchlist to track signal changes on your next visit.

Oruka Therapeutics, Inc. (ORKA) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 91.94%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
13 historical occurrences (since 2018-02-14)

Average forward return after Top-quintile 6-month momentum

20-day: Win 50%, Sample 12, Median -3.44%, Excess -9.23%, Beat mkt rate 25%

60-day: Win 25%, Sample 12, Median -14.21%, Excess -11.22%, Beat mkt rate 25%

120-day: Win 16.7%, Sample 12, Median -35.29%, Excess -19.52%, Beat mkt rate 16.7%

120 days after: historical avg -12.71%

20-day -8.72%
60-day -8.48%
120-day -12.71%
20-day
60-day
120-day
Win
50%
25%
16.7%
Sample
12
12
12
Median
-3.44%
-14.21%
-35.29%
Excess
-9.23%
-11.22%
-19.52%
Beat mkt rate
25%
25%
16.7%

Over 12 occurrences, 120-day forward avg declined 12.71%, lagged the market by 19.52 pts; win rate 16.7%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

10 times historically; 60-day forward avg +2.6%, win rate 50%, beating the market by -1.56 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

8 times historically; 60-day forward avg +25.01%, win rate 75%, beating the market by +21.1 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.